← Back to Search

Unknown

AND017 for Kidney Anemia

Phase 2
Waitlist Available
Research Sponsored by Kind Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and at week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose
Awards & highlights

Study Summary

This trial is studying a drug to see if it is safe and effective for patients with non-dialysis chronic kidney disease.

Eligible Conditions
  • Kidney Anemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and at week 3, 6, 9, 12, 14, and 28 days after the last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and at week 3, 6, 9, 12, 14, and 28 days after the last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing
Safety Evaluations
Secondary outcome measures
Change from baseline in Hb
Change in hemoglobin levels from baseline to the mean of weeks 10-13
Cumulative incidence of lack of response over the entire treatment period
+12 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: AND017 Dose CExperimental Treatment1 Intervention
AND017 will be administrated orally at dose C
Group II: AND017 Dose BExperimental Treatment1 Intervention
AND017 will be administrated orally at dose B
Group III: AND017 Dose AExperimental Treatment1 Intervention
AND017 will be administrated orally at dose A
Group IV: PlaceboPlacebo Group1 Intervention
Placebo will be administrated orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AND017
2021
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Kind Pharmaceuticals LLCLead Sponsor
8 Previous Clinical Trials
472 Total Patients Enrolled
Yusha Zhu, MD PhDStudy DirectorKind Pharmaceuticals LLC
3 Previous Clinical Trials
153 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial popular in the United States?

"Besides Flint, Michigan's Elite Research Center and Chattanooga, Tennessee's Southeast Renal Research Institute, this study is also being conducted in Clinical Advancement Center, PLLC of San Antonio, Texas among 7 other research facilities."

Answered by AI

By what means does this experiment seek to impact the medical field?

"The goal of this study is to measure the rate of rise in hemoglobin over a period of 17 weeks. Secondary outcomes include mean Hb levels at weeks 6-14, transferrin saturation (TSAT) level during treatment, and serum iron level during treatment."

Answered by AI

Could you tell me if the age limit for this particular clinical trial is 60 years old?

"The target participants for this clinical trial are people who fall between 20 and 74 years old."

Answered by AI

For whom is this clinical trial designed?

"The current trial taking place is testing a new medication for those who have kidney diseases and are between the ages 20 to 74. There are only 88 spots available in total."

Answered by AI

What are the short- and long-term effects of AND017 on humans?

"AND017's safety is estimated to be a 2. This is because, although there is some evidence that the drug is safe, there are no data suggesting that it is effective."

Answered by AI

Are people currently enrolling in this trial?

"From what is posted on clinicaltrials.gov, it appears that this trial is searching for participants. The trial was originally posted on October 18th 2021 and the most recent update was on July 5th, 2022."

Answered by AI

Who else is applying?

What state do they live in?
North Carolina
How old are they?
65+
What site did they apply to?
Metrolina Nephrology Associates
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I am open to advancement, and related trials.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
2021. "A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05035641.
~32 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top